comorbidities and treatment decisions in myelofibrosis
Published 2 years ago • 663 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:01
latest advances in myelofibrosis treatment
-
1:05
the importance of using mrd to guide treatment decisions in all
-
1:06
origins and treatment options for anemia in myelofibrosis
-
3:48
jak inhibition for the early treatment of myelofibrosis
-
1:13:17
professor chris fegan chairs a discussion on living well with cll.
-
5:10
what are the treatment options for myelofibrosis?
-
6:44
how does jakafi® (ruxolitinib) work?
-
1:26
the impact of comorbidity burden on treatment decisions in cll
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
3:19
first-line treatment selection in myelofibrosis
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
2:25
key ebmt guideline updates for the treatment and prophylaxis of gvhd
-
2:13
splicing mutations in post-et/post-pv myelofibrosis
-
1:14
insights into the management of mds/mpn overlap syndromes & advice for clinicians
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib